At North Shore Weight Loss, many patients report feeling better both physically and mentally while taking GLP-1 medications like semaglutide or tirzepatide. These improvements are often attributed to enhanced self-esteem due to weight loss, although there are signs that the medications may directly impact mental health. Long-term users have noted significant positive life changes and mental health improvements linked to their treatment. Recent studies reinforce these observations, suggesting that GLP-1 medications may not only aid in weight loss but could also be effective in treating symptoms of depression and anxiety.

GLP-1 receptor agonist medications like semaglutide and tirzepetide, known for treating obesity and type 2 diabetes, are now being explored for their potential to reduce cancer risk. Research suggests these medications may positively affect immune cells known as natural killer (NK) cells, which play a key role in fighting cancer. Initial studies show that even without significant weight loss, GLP-1 medications can improve NK cell function, enhancing their ability to combat cancer cells. While these findings are promising, more research is needed to fully understand the benefits and mechanisms. This emerging area could offer new ways to manage not just diabetes and obesity but also cancer prevention.

GLP-1 receptor agonists like semaglutide and liraglutide (Wegovy, Ozempic, Saxenda) demonstrate sustained weight management capabilities, even after discontinuation. Studies involving thousands of patients reveal that a significant majority—over 55%—maintain or further their weight loss one year post-treatment. These findings underscore the potential of these medications for long-term weight management, though the decision to use them should consider both their benefits and the still uncertain long-term risks, in consultation with healthcare providers.